Medical device firm BioVentrix has received CE mark approval for its Revivent TC transcatheter ventricular enhancement system.
After a myocardial infarction or heart attack, the Revivent system implants micro-anchor pairs to omit scarred myocardium from the healthy tissue of the left ventricle (LV).
Revivent TC system will be placed through the live procedure, eliminating the need for more invasive surgery.
Via a closed-chest and endovascular approach, the small titanium anchors will be placed along the outer surface of the heart and along one of the interior walls.
Later, the anchors will be pulled toward one another to effectively exclude the scarred and non-functioning heart wall.
BioVentrix president and CEO Kenneth Miller said: "The certification for CE marking is not only an important milestone for the company, but also for those who treat heart failure.
"More importantly, it transforms the spectrum of treatment by offering a minimally invasive therapeutic solution for the previously ignored ventricle.
"By making this critical treatment available, we are giving physicians an important additional resource that they can utilize in conjunction with existing valvular and vascular therapies, making Guideline-Directed Medical Therapy (GDMT) even more effective."